经尿道膀胱肿瘤电切术联合术后吡柔比星即刻膀胱灌注对非肌层浸润性膀胱癌的治疗效果分析被引量：8

在线阅读下载PDF

导出

摘要目的探讨经尿道膀胱肿瘤电切术联合术后吡柔比星即刻膀胱灌注对非肌层浸润性膀胱癌的治疗效果。方法选取2015年1月至2016年12月郑州大学第一附属医院收治的非肌层浸润性膀胱癌患者84例,按入院时间分为观察组(55例)和对照组(29例)。对照组患者接受经尿道膀胱肿瘤电切术+术后常规吡柔比星膀胱灌注治疗,观察组患者接受经尿道膀胱肿瘤电切术+术后吡柔比星即刻膀胱灌注治疗。治疗结束后,随访3~36个月,比较两组患者术后并发症发生情况及术后复发情况。结果观察组患者术后膀胱刺激征、血尿、发热、拔管后膀胱过度活动症、较严重泌尿系感染发生率及术后复发率均低于对照组,差异有统计学意义(P<0.05)。结论经尿道膀胱肿瘤电切术联合术后吡柔比星即刻膀胱灌注对非肌层浸润性膀胱癌的治疗效果好,术后并发症发生率及术后复发率均较低,值得临床推广。

作者白恒舟乔保平

机构地区郑州大学第一附属医院泌尿外科

出处《河南医学研究》 CAS 2017年第20期3706-3707,共2页 Henan Medical Research

关键词经尿道膀胱肿瘤电切术吡柔比星膀胱灌注非肌层浸润性膀胱癌

分类号 R737.14 [医药卫生—肿瘤]

作者简介通讯作者：乔保平,E-mail：zhangyaling＠zzu.edu.cn.

引文网络
相关文献

参考文献5

1田野.膀胱内药物灌注对浅表性膀胱癌术后复发的影响[J].中国基层医药,2017,24(2):235-238. 被引量：8
2曹倪豪,周飞,张锦华,宋杰,赵卫,杨菲,杨剑波.吡柔比星术后即刻膀胱灌注联合复方苦参注射液治疗浅表性膀胱癌的机制研究[J].海南医学院学报,2017,23(2):189-192. 被引量：16
3薛斌,何秉勋,康厚彬,朱智虎.经尿道膀胱肿瘤电切术联合吡柔比星膀胱灌注治疗对浅表性膀胱癌患者预后及血清相关因子的影响[J].实用癌症杂志,2016,31(6):1027-1029. 被引量：50
4韩兴涛,杨锦建,霍庆祥,魏澎涛,张寒.电切术联合吡柔比星膀胱灌注对浅表性膀胱癌疗效[J].中国内镜杂志,2015,21(5):494-497. 被引量：37
5张涛,湛海伦,杨飞,周祥福.吡柔比星术后早期与常规膀胱灌注对浅表性膀胱癌患者血清学指标的影响[J].海南医学院学报,2015,21(7):991-994. 被引量：23

二级参考文献42

1鄢阳,郑军华,许云飞,张海民,黄建华,彭波,高其若,黄国华,巢月根,孔宪国.膀胱癌组织中MMP-2、MMP-9、VEGF和RECK基因的表达及临床意义[J].第二军医大学学报,2007,28(10):1075-1078. 被引量：11
2ARAKAWA M, NAKAMURA K, YAMADA Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect[J]. Exp Ther Med, 2011, 2(5): 901-905.
3XYLINAS E, SHARIAT SF. Words of wisdom: Re: Prospective randomized phase II trial of a single early intravesical instillation ofpirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upperurinary tract urothelial carcinoma: the THP Monotherapy Study Group trial [J]. Eur Urol, 2013, 64 (4): 683-684.
4NAGASHIMA M, ARAKI A, YANAGISAWA M, et al. Effect of prophylactic intravesical instillation of pirarubicin to prevent re- current bladder tumors following nephrouretereetomy for upper urinary tract cancer[J]. Hinyokika Kiyo, 2013, 59(4): 213-216.
5BHATTACHARYA A, LI Y, SHI Y, et al. Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination [J]. Carcinogenesis, 2013, 34(11): 2593-2599.
6ARAKAWA M, NAKAMURA K, YAMADA Y, et al. Intravesical administration of pirarubicin against superficial bladder cancer:. relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect [J]. Exp Ther Med, 2011, 2 (5): 901-905.
7LIU W, CAO Y, FERN?NDEZ MI, et al. Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo[J]. Int Urol Nephrol, 2011, 43(3): 721-727.
8MARUYAMA T, HIGUCHI Y, SUZUKI T, et al. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells[J]. J Infect Chemother, 2011, 17 (1): 11-16.
9Pacheco-Figueiredo L,Antunes L,Bento MJ,et al.Evaluation of the frequency of and survival from second primary cancers in North Portugal:apopulation-based study[J].Eur J Cancer Prev,2013,22(6):599-606.
10Allchorne P,Lamb BW,Kinsella J,et al.Initial experience of intravesical gemcitabine for patients with high-risk superficial transitional cell carcinoma of the bladder following BCG failure[J].Urol Nurs,2014,34(2):95-99.